Urinary Metabolomics to Identify a Unique Biomarker Panel for Detecting Colorectal Cancer: A Multicenter Study.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
14
01
2019
revised:
29
03
2019
accepted:
28
05
2019
pubmed:
4
6
2019
medline:
18
9
2020
entrez:
2
6
2019
Statut:
ppublish
Résumé
Population-based screening programs are credited with earlier colorectal cancer diagnoses and treatment initiation, which reduce mortality rates and improve patient health outcomes. However, recommended screening methods are unsatisfactory as they are invasive, are resource intensive, suffer from low uptake, or have poor diagnostic performance. Our goal was to identify a urine metabolomic-based biomarker panel for the detection of colorectal cancer that has the potential for global population-based screening. Prospective urine samples were collected from study participants. Based upon colonoscopy and histopathology results, 342 participants (colorectal cancer, 171; healthy controls, 171) from two study sites (Canada, United States) were included in the analyses. Targeted liquid chromatography-mass spectrometry (LC-MS) was performed to quantify 140 highly valuable metabolites in each urine sample. Potential biomarkers for colorectal cancer were identified by comparing the metabolomic profiles from colorectal cancer versus controls. Multiple models were constructed leading to a good separation of colorectal cancer from controls. A panel of 17 metabolites was identified as possible biomarkers for colorectal cancer. Using only two of the selected metabolites, namely diacetylspermine and kynurenine, a predictor for detecting colorectal cancer was developed with an AUC of 0.864, a specificity of 80.0%, and a sensitivity of 80.0%. We present a potentially "universal" metabolomic biomarker panel for colorectal cancer independent of cohort clinical features based on a North American population. Further research is needed to confirm the utility of the profile in a prospective, population-based colorectal cancer screening trial. A urinary metabolomic biomarker panel was identified for colorectal cancer with the potential of clinical application.
Sections du résumé
BACKGROUND
Population-based screening programs are credited with earlier colorectal cancer diagnoses and treatment initiation, which reduce mortality rates and improve patient health outcomes. However, recommended screening methods are unsatisfactory as they are invasive, are resource intensive, suffer from low uptake, or have poor diagnostic performance. Our goal was to identify a urine metabolomic-based biomarker panel for the detection of colorectal cancer that has the potential for global population-based screening.
METHODS
Prospective urine samples were collected from study participants. Based upon colonoscopy and histopathology results, 342 participants (colorectal cancer, 171; healthy controls, 171) from two study sites (Canada, United States) were included in the analyses. Targeted liquid chromatography-mass spectrometry (LC-MS) was performed to quantify 140 highly valuable metabolites in each urine sample. Potential biomarkers for colorectal cancer were identified by comparing the metabolomic profiles from colorectal cancer versus controls. Multiple models were constructed leading to a good separation of colorectal cancer from controls.
RESULTS
A panel of 17 metabolites was identified as possible biomarkers for colorectal cancer. Using only two of the selected metabolites, namely diacetylspermine and kynurenine, a predictor for detecting colorectal cancer was developed with an AUC of 0.864, a specificity of 80.0%, and a sensitivity of 80.0%.
CONCLUSIONS
We present a potentially "universal" metabolomic biomarker panel for colorectal cancer independent of cohort clinical features based on a North American population. Further research is needed to confirm the utility of the profile in a prospective, population-based colorectal cancer screening trial.
IMPACT
A urinary metabolomic biomarker panel was identified for colorectal cancer with the potential of clinical application.
Identifiants
pubmed: 31151939
pii: 1055-9965.EPI-18-1291
doi: 10.1158/1055-9965.EPI-18-1291
pmc: PMC6677589
mid: NIHMS1530837
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1283-1291Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIBIB NIH HHS
ID : UG3 EB024965
Pays : United States
Organisme : NCI NIH HHS
ID : UH3 CA257869
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Int J Cancer. 2009 May 15;124(10):2406-15
pubmed: 19142968
Int J Colorectal Dis. 2012 Dec;27(12):1657-64
pubmed: 22696204
Biomed Res Int. 2013;2013:303982
pubmed: 24307992
Front Hum Neurosci. 2018 Jun 04;12:226
pubmed: 29915533
Br J Cancer. 2015 Nov 17;113(10):1493-501
pubmed: 26505680
Cancers (Basel). 2018 Jul 27;10(8):
pubmed: 30060469
Patient Prefer Adherence. 2018 Sep 18;12:1825-1836
pubmed: 30271126
Anticancer Res. 2018 Jun;38(6):3601-3607
pubmed: 29848716
Gastroenterology. 2018 Nov;155(5):1302-1304
pubmed: 30300613
J Cancer. 2016 Oct 8;7(14):1984-2004
pubmed: 27877214
Clin Transl Gastroenterol. 2014 Mar 20;5:e54
pubmed: 24646506
Gut. 2015 Oct;64(10):1637-49
pubmed: 26041752
Colorectal Dis. 2018 Dec;20(12):O335-O342
pubmed: 30248228
Front Pharmacol. 2014 Jan 10;4:175
pubmed: 24454288
J Proteome Res. 2014 Sep 5;13(9):3857-70
pubmed: 25105552
JAMA Intern Med. 2018 Dec 1;178(12):1645-1658
pubmed: 30326005
Ann Intern Med. 2002 May 7;136(9):652-9
pubmed: 11992300
Dig Liver Dis. 2005 Mar;37(3):190-4
pubmed: 15888284
Gastroenterology. 2018 Nov;155(5):1383-1391.e5
pubmed: 30031768
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Clin Pract Epidemiol Ment Health. 2018 Mar 21;14:63-69
pubmed: 29643929
BMC Bioinformatics. 2011 Jun 22;12:253
pubmed: 21693065
Mol Diagn Ther. 2017 Apr;21(2):225-232
pubmed: 28155091
Am J Gastroenterol. 2018 May;113(5):746-754
pubmed: 29487413
CMAJ Open. 2015 Apr 02;3(2):E149-57
pubmed: 26389092
World J Gastroenterol. 2017 May 28;23(20):3632-3642
pubmed: 28611516
Mass Spectrom Rev. 2012 Jan-Feb;31(1):49-69
pubmed: 21374694
Sci Rep. 2018 Jan 8;8(1):36
pubmed: 29311683
Int J Mol Sci. 2018 Mar 07;19(3):
pubmed: 29518931
Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):140-7
pubmed: 21098649
Metabolomics. 2017;13(1):4
pubmed: 27980503
Clin Cancer Res. 2005 Apr 15;11(8):2986-90
pubmed: 15837752
Int J Biol Markers. 2004 Oct-Dec;19(4):322-7
pubmed: 15646840
Int J Colorectal Dis. 2017 May;32(5):741-743
pubmed: 27909808
Gastroenterol Clin North Am. 2013 Sep;42(3):639-57
pubmed: 23931864
Anal Chim Acta. 2018 Nov 30;1034:110-118
pubmed: 30193624
ISRN Endocrinol. 2013 Oct 09;2013:893913
pubmed: 24224095
Oncotarget. 2017 May 23;8(21):35460-35472
pubmed: 28389626
Nucleic Acids Res. 2018 Jul 2;46(W1):W486-W494
pubmed: 29762782
N Engl J Med. 2014 Apr 3;370(14):1287-97
pubmed: 24645800
Can Med Assoc J. 1955 Aug 1;73(3):198-201
pubmed: 13240580
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Nov;150(2):235-7
pubmed: 17426784
N Engl J Med. 2012 Feb 23;366(8):697-706
pubmed: 22356323
Int J Epidemiol. 2016 Oct;45(5):1507-1516
pubmed: 27694567
Metabolites. 2017 Jun 22;7(3):
pubmed: 28640228
Gut. 2013 Mar;62(3):409-15
pubmed: 22387523
Anal Chim Acta. 2017 Jan 25;951:99-107
pubmed: 27998490